Valuation: Gennex Laboratories Limited

Market Cap 1.73B 18.11M 15.5M 14.51M 13.28M 24.99M 25.25M 172M 66.78M 870M 67.97M 66.49M 2.88B P/E 2024
26x
P/E 2025 15.4x
Enterprise Value 1.46B 15.23M 13.04M 12.2M 11.17M 21.02M 21.25M 144M 56.19M 732M 57.19M 55.95M 2.42B EV / Sales 2024
3.67x
EV / Sales 2025 1.79x
Free-Float
63.52%
Yield 2024 *
-
Yield 2025 -
08-14 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-30 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Gennex Laboratories Limited Resignation of Shilpa Bung, Non-Executive Independent Women Director, Effective February 14, 2026 CI
02-14 Gennex Laboratories Limited Appoints Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) CI
02-14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/08/25 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/05/25 Gennex Laboratories Limited Announces Resignation of Dr. Sch Dharma Rao as Non-Executive Non-Independent Director, Effective May 30, 2025 CI
30/05/25 Gennex Laboratories Limited Appoints Sandeep Kumar Daga as Non-Executive Non-Independent Director CI
30/05/25 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
14/02/25 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
14/02/25 Gennex Laboratories Limited Announces Resignation of Mohammed Khaleequr Rahman as Non-Executive Non-Independent Director CI
15/11/24 Gennex Laboratories Limited Approves the Appointment of Akkali Santosh Kumar as Chief Financial Officer CI
1 day+8.21%
1 week+17.01%
Current month+42.89%
1 month+39.89%
3 months+3.18%
6 months+8.30%
Current year-11.47%
1 week 9.51
Extreme 9.51
12.89
1 month 8.25
Extreme 8.25
12.89
Current year 7.05
Extreme 7.05
14.77
1 year 7.05
Extreme 7.05
17.25
3 years 7.05
Extreme 7.05
29
5 years 4.81
Extreme 4.81
29
10 years 1.32
Extreme 1.32
29
Manager TitleAgeSince
Chief Executive Officer 40 18/05/2012
Director of Finance/CFO - 12/11/2024
Compliance Officer 62 20/04/2023
Director TitleAgeSince
Chairman 40 -
Director/Board Member - 21/12/2020
Director/Board Member - 21/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
+8.21%+17.01%+4.89%+51.62% 32.15M
+0.88%+6.38%+76.40%+126.75% 1,119B
+1.07%+3.80%+50.73%+62.78% 651B
+1.20%+6.21%+25.81%+78.74% 468B
+1.02%+5.77%+43.63%+48.43% 374B
+0.85%+4.07%+24.97%+40.58% 302B
+1.26%+6.81%+2.27%+14.41% 259B
+1.88%+5.81%+49.57%+70.53% 238B
+1.59%+2.09%-17.33%-52.62% 208B
+1.87%+5.61%+27.32%+91.38% 181B
Average +1.98%+6.18%+28.83%+53.26% 379.99B
Weighted average by Cap. +1.14%+5.09%+44.26%+72.65%

Financials

2024 2025
Net sales 867M 9.06M 7.76M 7.26M 6.65M 12.51M 12.64M 85.89M 33.43M 435M 34.03M 33.29M 1.44B 1.38B 14.41M 12.34M 11.55M 10.57M 19.89M 20.1M 137M 53.16M 693M 54.11M 52.94M 2.29B
Net income 132M 1.38M 1.18M 1.1M 1.01M 1.9M 1.92M 13.05M 5.08M 66.17M 5.17M 5.06M 219M 181M 1.89M 1.62M 1.52M 1.39M 2.61M 2.64M 17.95M 6.99M 91.01M 7.11M 6.96M 301M
Net Debt -413M -4.32M -3.7M -3.46M -3.17M -5.96M -6.02M -40.9M -15.92M -207M -16.2M -15.85M -686M -275M -2.87M -2.46M -2.3M -2.11M -3.96M -4.01M -27.21M -10.59M -138M -10.78M -10.55M -457M
Logo Gennex Laboratories Limited
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Employees
115
Date Price Change Volume
21/08/26 ₹12.66 +8.21% 4,069,199
20/08/26 ₹11.70 -0.59% 574,883
19/08/26 ₹11.77 -1.92% 807,728
18/08/26 ₹12.00 0.00% 2,012,969
17/08/26 ₹12.00 +10.91% 5,202,735
  1. Stock Market
  2. Stocks
  3. GENNEX6 Stock